DNLI Stock Analysis: Buy, Sell, or Hold?
DNLI - Denali Therapeutics Inc. Common Stock
$23.95
2.02 (9.21%)
▲
5d:
+16.21%
30d:
+30.16%
90d:
+19.39%
HOLD
MODERATE Confidence
Analysis Updated: Jun 16, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Smart Money Distribution
None View Scanner →
Strength: 7.6/10
Get Alerted When DNLI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: DNLI is 12.2% above its trading range ($21.35). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: DNLI is 12.2% above its trading range ($21.35). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: DNLI is currently trading at $23.95, which is considered extended relative to its 30-day fair value range of $18.82 to $21.35.
Technical Outlook: Technically, DNLI is in a uptrend. The price is approaching resistance at $24.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: DNLI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.93 (+54.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DNLI is in a uptrend. The price is approaching resistance at $24.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: DNLI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $33.93 (+54.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$18.82 -
$21.35
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+12.2% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.2%)
- BULLISH: Trading 54.7% below Wall St target ($33.93)
Trading Range Analysis
30-Day Trading Range
$18.82 -
$21.35
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$19.19
Resistance Level
$24.21
Current Trend
Uptrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.85
Wall Street Target
$33.93
(+54.7%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 17, 2026 1:38 PM ET
Data refreshes hourly during market hours. Next update: 2:38 PM
Data refreshes hourly during market hours. Next update: 2:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNLI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Alexander O Schuth
SELL
17218 shares
2026-01-06
Ryan J Watts
SELL
35198 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 60 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 60 HOLD |
